Hospital
Sunrise Hospital and Medical Center, LLC
Sunrise Hospital and Medical Center, LLC was paid $85.83M by Medicaid between Jan 2018 and Dec 2024, across 372 billing codes. Its largest line is 99283, emergency room visit (moderate) — 20% of everything it billed.
33Billing provider infoSUNRISE HOSPITAL AND MEDICAL CENTER, LLC
LAS VEGAS, NV 89109
LAS VEGAS, NV 89109
33aNPI1861439952assigned 05/31/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$85.83M
24GClaims2,925,892
24DCodes billed372
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Nevada
Rank by total paid#2 of 36
Median peer was paid$7.64M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 149,279 | $5.20M | |
| 2019 | 470,689 | $13.23M | |
| 2020 | 434,709 | $11.66M | |
| 2021 | 465,945 | $12.91M | |
| 2022 | 450,894 | $14.64M | |
| 2023 | 469,587 | $13.87M | |
| 2024incomplete | 484,789 | $14.33M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 191,675 | 168,256 | $17.41M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 135,188 | 120,637 | $13.93M |
| G0378 | Hospital observation service, per hour | 8.9% | 38,143 | 20,398 | $7.66M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.7% | 43,832 | 37,560 | $4.91M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.5% | 46,960 | 44,632 | $3.84M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.9% | 63,244 | 56,147 | $2.52M |
| 93975 | 2.8% | 15,158 | 13,447 | $2.39M | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 18,449 | 17,153 | $2.32M |
| 54161 | 2.0% | 2,891 | 2,744 | $1.72M | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.7% | 35,307 | 27,572 | $1.43M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.3% | 34,182 | 26,562 | $1.08M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 12,138 | 11,374 | $1.05M |
360 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 23,836 | $1.05M |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 52,943 | $1.01M |
| 54300 | 1.0% | 732 | $864K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 34,013 | $838K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 32,937 | $780K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,927 | $674K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 8,943 | $618K |
| 80053 | Comprehensive metabolic panel | <1% | 109,691 | $618K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,512 | $564K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 42,001 | $542K |
| 44970 | <1% | 377 | $533K | |
| 54360 | <1% | 737 | $533K | |
| 71045 | Radiologic examination, chest; single view | <1% | 56,173 | $522K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 13,625 | $516K |
| 85027 | <1% | 175,061 | $405K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 505 | $404K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 93,357 | $401K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 19,282 | $397K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 10,931 | $390K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 6,676 | $377K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 17,255 | $368K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 6,650 | $348K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,502 | $335K |
| 76830 | Ultrasound, transvaginal | <1% | 5,762 | $320K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,331 | $320K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 55,401 | $279K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 6,381 | $273K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 7,826 | $273K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 6,838 | $262K |
| 74018 | <1% | 13,481 | $253K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 17,309 | $252K |
| 14040 | <1% | 1,614 | $251K | |
| 84484 | <1% | 56,696 | $240K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,132 | $229K |
| 87400 | <1% | 16,630 | $229K | |
| 70486 | <1% | 2,865 | $224K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,123 | $222K |
| 83880 | <1% | 17,209 | $222K | |
| 76770 | <1% | 2,886 | $210K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,525 | $194K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 79,065 | $188K |
| 87150 | <1% | 1,043 | $188K | |
| 12011 | <1% | 2,715 | $186K | |
| 10060 | <1% | 1,813 | $179K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 362 | $167K |
| 15002 | <1% | 295 | $165K | |
| 84703 | <1% | 49,850 | $156K | |
| 12001 | <1% | 2,659 | $155K | |
| 81001 | <1% | 81,230 | $154K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 29,971 | $153K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 5,635 | $144K |
| 74019 | <1% | 5,159 | $142K | |
| 0450 | Emergency room services | <1% | 3,123 | $140K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,060 | $138K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 26,814 | $137K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,158 | $135K |
| 93971 | <1% | 3,065 | $129K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,164 | $129K |
| 80047 | <1% | 25,121 | $128K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,975 | $127K |
| 83690 | <1% | 46,348 | $121K | |
| 93970 | <1% | 1,901 | $119K | |
| 54304 | <1% | 115 | $113K | |
| 73564 | <1% | 6,001 | $112K | |
| 47562 | <1% | 67 | $110K | |
| 95819 | <1% | 486 | $109K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,343 | $107K |
| 87040 | <1% | 23,301 | $107K | |
| 96376 | <1% | 14,853 | $106K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,577 | $103K |
| 80076 | <1% | 24,699 | $101K | |
| 73130 | <1% | 6,114 | $95K | |
| 12002 | <1% | 1,500 | $93K | |
| 70491 | <1% | 1,016 | $92K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,489 | $88K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 18,543 | $87K |
| 84702 | <1% | 14,510 | $85K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 2,476 | $83K |
| 73630 | <1% | 5,898 | $82K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,186 | $81K |
| 29125 | <1% | 1,522 | $79K | |
| 87430 | <1% | 14,877 | $78K | |
| 73610 | <1% | 5,015 | $76K | |
| 70498 | <1% | 506 | $72K | |
| 85610 | <1% | 46,905 | $72K | |
| 82550 | <1% | 25,846 | $71K | |
| 87486 | <1% | 5,590 | $71K | |
| 87581 | <1% | 5,581 | $68K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 1,872 | $67K |
| 72100 | <1% | 4,633 | $67K | |
| 87070 | <1% | 11,756 | $66K | |
| 85730 | <1% | 32,469 | $66K | |
| 15004 | <1% | 125 | $61K | |
| 70496 | <1% | 430 | $61K | |
| 83605 | <1% | 13,117 | $59K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 6,395 | $56K |
| 73110 | <1% | 2,909 | $54K | |
| 81025 | <1% | 18,368 | $53K | |
| 73030 | <1% | 4,173 | $53K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 26,990 | $44K |
| 73090 | <1% | 3,272 | $44K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 27,680 | $41K |
| 73080 | <1% | 2,607 | $41K | |
| 76870 | <1% | 1,690 | $40K | |
| 97163 | <1% | 1,893 | $37K | |
| 97162 | <1% | 1,451 | $36K | |
| 73590 | <1% | 3,083 | $36K | |
| 83735 | <1% | 18,502 | $36K | |
| 81003 | <1% | 19,184 | $35K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,087 | $34K |
| 90715 | <1% | 1,634 | $34K | |
| 72072 | <1% | 2,158 | $34K | |
| 82805 | <1% | 3,539 | $34K | |
| 87077 | <1% | 7,599 | $32K | |
| 73502 | <1% | 2,062 | $32K | |
| 72050 | <1% | 1,582 | $31K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,759 | $31K |
| 87420 | <1% | 4,878 | $29K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,197 | $29K |
| 84112 | <1% | 1,529 | $28K | |
| 93017 | <1% | 1,514 | $27K | |
| 71101 | <1% | 1,531 | $26K | |
| 87186 | <1% | 5,379 | $25K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 36,280 | $24K |
| 93458 | <1% | 70 | $24K | |
| 76536 | <1% | 455 | $22K | |
| 72131 | <1% | 441 | $22K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 4,342 | $21K |
| 86140 | <1% | 11,676 | $21K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,828 | $21K |
| 86901 | <1% | 21,033 | $21K | |
| 86900 | <1% | 21,024 | $21K | |
| J3490 | Unclassified drugs | <1% | 3,171 | $20K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 830 | $20K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,588 | $19K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 4,433 | $19K |
| 85379 | <1% | 5,070 | $18K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 4,031 | $18K |
| 86850 | <1% | 12,073 | $18K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 40,664 | $17K |
| 73552 | <1% | 1,337 | $17K | |
| 96368 | <1% | 3,938 | $17K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,331 | $16K |
| 97161 | <1% | 841 | $16K | |
| 74021 | <1% | 926 | $15K | |
| 75574 | <1% | 56 | $15K | |
| 97167 | <1% | 585 | $15K | |
| 99070 | <1% | 1,402 | $15K | |
| 86923 | <1% | 1,593 | $14K | |
| 73060 | <1% | 1,189 | $14K | |
| 97116 | <1% | 2,368 | $14K | |
| 29515 | <1% | 250 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,643 | $13K |
| 95700 | <1% | 110 | $13K | |
| 80061 | Lipid panel | <1% | 3,360 | $13K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 18,665 | $13K |
| 87205 | <1% | 7,164 | $13K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 26,419 | $13K |
| 24640 | <1% | 139 | $13K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,638 | $13K |
| 76857 | <1% | 623 | $12K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,433 | $12K |
| 82077 | <1% | 3,021 | $12K | |
| 80074 | <1% | 1,005 | $12K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 777 | $12K |
| 12013 | <1% | 199 | $11K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 140 | $11K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,771 | $10K |
| 99151 | <1% | 601 | $10K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 13,910 | $10K |
| J0456 | Injection, azithromycin, 500 mg | <1% | 3,960 | $9K |
| 90714 | <1% | 1,254 | $9K | |
| 82330 | <1% | 1,928 | $9K | |
| 80069 | <1% | 4,843 | $9K | |
| 87088 | <1% | 2,096 | $9K | |
| 16020 | <1% | 94 | $8K | |
| 72170 | <1% | 907 | $8K | |
| 82140 | <1% | 1,944 | $8K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,658 | $8K |
| 0250 | <1% | 867 | $8K | |
| 30300 | <1% | 38 | $8K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 7,336 | $8K |
| 69200 | <1% | 83 | $8K | |
| 86780 | <1% | 1,177 | $7K | |
| 96367 | <1% | 1,128 | $7K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,756 | $7K |
| 51600 | <1% | 28 | $6K | |
| 73000 | <1% | 432 | $6K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 648 | $6K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,776 | $6K |
| 73140 | <1% | 265 | $6K | |
| 84439 | <1% | 1,903 | $6K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,284 | $6K |
| 84100 | <1% | 5,658 | $5K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 7,235 | $5K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 25 | $5K |
| 82248 | <1% | 3,004 | $5K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,161 | $5K |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,657 | $5K |
| J1815 | Injection, insulin, per 5 units | <1% | 5,838 | $5K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,289 | $5K |
| 85384 | <1% | 1,667 | $5K | |
| 87808 | <1% | 1,655 | $5K | |
| 99152 | <1% | 780 | $5K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,509 | $4K |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 174 | $4K |
| 80320 | <1% | 1,607 | $4K | |
| 85651 | <1% | 3,139 | $4K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 94 | $4K |
| 88307 | <1% | 355 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 27 | $3K |
| 82728 | <1% | 916 | $3K | |
| 71250 | <1% | 54 | $3K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 4,216 | $3K |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 1,013 | $3K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 39 | $3K |
| 93320 | <1% | 136 | $3K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 116 | $3K |
| S0028 | Injection, famotidine, 20 mg | <1% | 5,193 | $3K |
| 76000 | <1% | 1,659 | $3K | |
| 70360 | <1% | 258 | $3K | |
| 15853 | <1% | 498 | $3K | |
| 29105 | <1% | 54 | $3K | |
| 94644 | <1% | 108 | $3K | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,063 | $3K |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | <1% | 818 | $3K |
| C1781 | Mesh (implantable) | <1% | 25 | $3K |
| 74175 | <1% | 26 | $3K | |
| 85007 | <1% | 1,675 | $3K | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 34 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,859 | $2K |
| 70487 | <1% | 39 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 357 | $2K |
| 84132 | <1% | 2,942 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 50 | $2K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,011 | $2K |
| 93880 | <1% | 30 | $2K | |
| 80055 | <1% | 15 | $2K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 135 | $2K |
| 93325 | <1% | 167 | $2K | |
| 15275 | <1% | 15 | $2K | |
| 86920 | <1% | 125 | $2K | |
| 92610 | <1% | 79 | $2K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 1,058 | $2K |
| 76881 | <1% | 40 | $2K | |
| 97166 | <1% | 73 | $2K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 81 | $2K |
| 82553 | <1% | 288 | $2K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 14 | $2K |
| 72128 | <1% | 27 | $2K | |
| 92523 | <1% | 13 | $2K | |
| 86308 | <1% | 481 | $2K | |
| 36430 | <1% | 98 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,266 | $1K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,669 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 824 | $1K |
| 74240 | <1% | 14 | $1K | |
| 93315 | <1% | 16 | $1K | |
| 83540 | <1% | 830 | $1K | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 308 | $1K |
| 83550 | <1% | 813 | $1K | |
| 85045 | <1% | 816 | $1K | |
| 88304 | <1% | 2,127 | $1K | |
| 83615 | <1% | 486 | $1K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 764 | $1K |
| 82009 | <1% | 591 | $1K | |
| 73560 | <1% | 99 | $1K | |
| 87210 | <1% | 163 | $1K | |
| 31720 | <1% | 12 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,647 | $944.27 |
| 82607 | <1% | 143 | $939.32 | |
| 82150 | <1% | 309 | $916.18 | |
| 73100 | <1% | 94 | $904.46 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,614 | $902.68 |
| 74455 | <1% | 28 | $881.12 | |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 111 | $840.00 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 67 | $835.44 |
| 82570 | <1% | 566 | $825.30 | |
| 87631 | <1% | 4,573 | $760.05 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,754 | $740.38 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,231 | $712.69 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 321 | $694.89 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 2,262 | $660.86 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,591 | $645.27 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 831 | $643.85 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 15 | $641.46 |
| 84550 | <1% | 384 | $632.45 | |
| 0270 | <1% | 52 | $611.63 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 12 | $583.44 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 117 | $580.82 |
| 0272 | <1% | 15 | $532.60 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 527 | $525.85 |
| 85018 | <1% | 1,861 | $479.82 | |
| 82310 | <1% | 230 | $468.16 | |
| 84156 | <1% | 414 | $440.69 | |
| 87147 | <1% | 318 | $435.60 | |
| 36600 | <1% | 120 | $431.42 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 946 | $429.00 |
| 88300 | <1% | 892 | $427.07 | |
| 77075 | <1% | 13 | $425.25 | |
| 86803 | <1% | 74 | $354.45 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 20 | $347.20 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 154 | $304.36 |
| 73070 | <1% | 69 | $241.34 | |
| 97597 | <1% | 45 | $192.69 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 51 | $191.88 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 170 | $187.86 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 401 | $185.74 |
| 84295 | <1% | 391 | $180.78 | |
| 87899 | <1% | 14 | $179.96 | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 13 | $174.78 |
| 85049 | <1% | 390 | $171.36 | |
| 87046 | <1% | 13 | $167.44 | |
| 82565 | <1% | 152 | $165.40 | |
| 87075 | <1% | 296 | $161.50 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 159 | $157.06 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 208 | $156.04 |
| C1769 | Guide wire | <1% | 2,429 | $153.90 |
| 88342 | <1% | 64 | $148.63 | |
| 73600 | <1% | 38 | $131.64 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 74 | $130.83 |
| 82947 | <1% | 295 | $107.54 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $100.00 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 16 | $91.70 |
| 82746 | <1% | 15 | $90.27 | |
| 85014 | <1% | 424 | $79.60 | |
| 82435 | <1% | 264 | $78.77 | |
| A9270 | Non-covered item or service | <1% | 22,590 | $74.39 |
| 87045 | <1% | 13 | $70.84 | |
| 72220 | <1% | 13 | $65.82 | |
| 82247 | <1% | 75 | $61.56 | |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | <1% | 97 | $59.18 |
| G0008 | Administration of influenza virus vaccine | <1% | 33 | $53.40 |
| J2800 | Injection, methocarbamol, up to 10 ml | <1% | 16 | $30.60 |
| S0030 | Injection, metronidazole, 500 mg | <1% | 62 | $29.40 |
| 51702 | <1% | 14 | $28.47 | |
| 80202 | <1% | 18 | $27.75 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 12 | $26.43 |
| 86592 | <1% | 17 | $26.19 | |
| S0191 | Misoprostol, oral, 200 mcg | <1% | 19 | $24.48 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 398 | $19.17 |
| C1758 | Catheter, ureteral | <1% | 80 | $6.90 |
| S5010 | 5% dextrose and 0.45% normal saline, 1000 ml | <1% | 30 | $5.60 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 75 | $2.78 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 15 | $1.70 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 16 | $1.01 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 1,644 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 26 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 529 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 1,287 | $0.00 |
| 88312 | 0% | 61 | $0.00 | |
| Q4227 | Amniocore, per square centimeter (add-on, list separately in addition to primary procedure) | 0% | 48 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 30 | $0.00 |
| C1849 | Skin substitute, synthetic, resorbable, per square centimeter | 0% | 17 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 156 | $0.00 |
| Q4100 | Skin substitute, not otherwise specified | 0% | 48 | $0.00 |
| 70320 | 0% | 199 | $0.00 | |
| 80329 | 0% | 47 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 33 | $0.00 |
| 64488 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJAMES, CARL (CFO)
| Provider | Location | Paid |
|---|---|---|
| High Desert Family Services, INC. | Albuquerque, NM | $15K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.